Comparative Pharmacology
Head-to-head clinical analysis: METHAMPHETAMINE HYDROCHLORIDE versus METHYLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHAMPHETAMINE HYDROCHLORIDE versus METHYLIN.
METHAMPHETAMINE HYDROCHLORIDE vs METHYLIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methamphetamine is a potent central nervous system stimulant that increases synaptic concentrations of dopamine, norepinephrine, and serotonin by reversing their transporters, inhibiting monoamine oxidase, and inhibiting vesicular monoamine transporter 2 (VMAT2).
Methylphenidate is a central nervous system stimulant. It blocks the reuptake of dopamine and norepinephrine into presynaptic neurons, increasing their concentrations in the synaptic cleft.
Oral: 5-10 mg once or twice daily, titrated up to a maximum of 60 mg/day in divided doses. Typical initial dose for ADHD: 5 mg once or twice daily, increase by 5 mg weekly; for obesity: 5 mg before meals, up to 30 mg/day.
10 mg orally twice daily, administered 4-6 hours apart; doses may be adjusted in 5-10 mg increments weekly up to 60 mg/day.
None Documented
None Documented
Terminal elimination half-life: 10-12 hours. Clinical context: Longer half-life than amphetamine (6-8 h) due to higher lipophilicity and tissue binding. Variability (4–30 h) depends on urine pH, dose, and chronic use (tissue accumulation).
2-4 hours (short elimination half-life, requiring multiple daily dosing; immediate-release: 3-4 hours, extended-release: 3-6 hours)
Primarily renal excretion of unchanged drug (30-50%) and metabolites (p-hydroxymethamphetamine, amphetamine, p-hydroxyamphetamine). Up to 70% eliminated over 24 hours. Renal clearance depends on urinary pH; acidic urine (pH <5) increases elimination, alkaline urine reduces it. Biliary/fecal excretion is minimal (<5%).
Renal: 90% (mainly as metabolites, 30-50% as unchanged drug); fecal: <1%
Category D/X
Category C
CNS Stimulant
CNS Stimulant